Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Single arterial occlusion to locate resistance in patients with pulmonary hypertension

P. Fesler, A. Pagnamenta, J‐L. Vachiéry, S. Brimioulle, S. Abdel Kafi, A. Boonstra, M. Delcroix, R.N. Channick, L.J. Rubin, R. Naeije
European Respiratory Journal 2003 21: 31-36; DOI: 10.1183/09031936.03.00054202
P. Fesler
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Pagnamenta
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J‐L. Vachiéry
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Brimioulle
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Abdel Kafi
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Boonstra
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Delcroix
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.N. Channick
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L.J. Rubin
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Naeije
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

The purpose of this study was to determine the site of increased resistance using the arterial occlusion technique in patients with severe pulmonary hypertension.

Pulmonary vascular resistance was partitioned in arterial and venous components based on double exponential fitting analysis of the pulmonary artery pressure decay curve: after balloon occlusion in 36 patients with pulmonary arterial hypertension (PAH); at baseline and during the inhalation of 20 parts per million of nitric oxide (NO); in four patients with chronic thromboembolic pulmonary hypertension; and in two patients with pulmonary veno-occlusive disease.

In the patients with PAH, at baseline, mean pulmonary artery pressure was 56±2 mmHg (mean±se), with an arterial component of resistance of 63±1%. Inhaled NO did not change the partition of resistance. The arterial component of resistance amounted on average to 42% and 77% in the patients with veno‐occlusive disease and the patients with thromboembolic pulmonary hypertension, respectively. However, the partitioning of resistance did not discriminate between these three diagnostic categories.

The occlusion technique may help to locate the predominant site of increased resistance in patients with severe pulmonary hypertension, but does not allow for a satisfactory differential diagnosis on an individual basis.

  • chronic thromboembolic pulmonary hypertension
  • effective pulmonary capillary pressure
  • nitric oxide
  • pulmonary arterial hypertension
  • pulmonary vascular resistance
  • pulmonary veno-occlusive disease

Supported by grant number 3.4567.00 from the Fonds de la Recherche Scientifique Médicale, Brussels, Belgium. P. Fesler was a fellow of the Erasmus Foundation, Brussels, Belgium.

The occlusion technique can be used in intact animals and patients for the partitioning of pulmonary vascular resistance (PVR) into an arterial segment (PVRa) and a capillary-venous segment, and for the determination of an effective pulmonary capillary pressure (Pc) 1, 2. The method identified a hydrostatic mechanism, with an important role accounting for early high-altitude pulmonary oedema 3. The single arterial occlusion technique applied to a small series of patients with primary pulmonary hypertension (PPH) showed a longitudinal distribution of resistance that appeared similar to that found in normal pulmonary circulation, with a PVRa ∼55% of PVR 4. This was interpreted as being compatible with pathological changes that dominate at the site of the smallest arterioles 4. A surprise finding was an absolute value for Pc of ∼30 mmHg, potentially associated with increased capillary filtration. Lung oedema is not known to be a frequent occurrence in patients with PPH 5.

In the study by Kafi et al. 4, pulmonary artery pressure (Ppa) decay curves after arterial occlusion were analysed using a single exponential fitting procedure derived from a simple model of the pulmonary circulation made up of arterial and venous resistances around a capillary capacitance 6. Theoretically, this approach can be improved using a double exponential fitting based on a more realistic model of the distribution of arterial, capillary and venous resistances and capacitances 7.

It was therefore of interest to compare both methods in a larger number of patients to check whether previously described increased Pc might be a methodological artefact. Not only patients with “pure” PPH, but also with pulmonary arterial hypertension (PAH), as defined by a recent World Health Organization-sponsored consensus conference 8, were included. The study sought to determine whether Pc, as computed with optimal methodology, might be better correlated with clinical state than traditionally measured Ppa and PVR. For the purpose of comparison, Pc was also measured by arterial occlusion in two patients with pulmonary veno-occlusive disease (PVOD) and in four patients with chronic thromboembolic pulmonary hypertension (CTEPH). An increased venous resistance would be expected to increase Pc at a given Ppa, and to prolong the Ppa decay curve after occlusion. Conversely, an increase in proximal resistance, as seen in CTEPH, would be expected to shorten the Ppa decay curve after occlusion, leading to decreased Pc at a given Ppa.

Methods

Patients

Forty-two patients, 12 males and 31 females aged 52±14 yrs (mean±sd) gave informed consent to this study. The study was approved by the institutional review boards of the Erasme University Hospital (Brussels, Belgium), and the Gasthuisberg University Hospital (Leuven, Belgium) and the UCSD Medical Center (San Diego, CA, USA) and conformed with the principles outlined in the Declaration of Helsinki. All of the patients had a Ppa of >25 mmHg at rest. Thirty-six patients fitted into the diagnostic criteria of PAH as defined by a recent World Health Organization-sponsored consensus conference that extended the concept of PPH to associated conditions, including collagen vascular diseases, congenital systemic-to-pulmonary shunts, human immunodeficiency virus (HIV) infection, anorexigen intake, and portal hypertension 8. From those 36 patients, 19 had PPH, 11 had pulmonary hypertension (PH) associated with anorexigens, three had portal PH, and three had PH associated with scleroderma. Two patients, a 16-yr-old male and a female aged 43 yrs, were suffering from PVOD. This diagnosis rested on radiological signs of interstitial and alveolar oedema, which were markedly aggravated in the male shortly after an attempt at prostacyclin therapy. The diagnosis of PVOD was confirmed in the female by an open lung biopsy. Four patients had an angiographically diagnosed CTEPH. Their pre-operative tracings were included in the present study on the basis of absent or minimal PH, with a mean Ppa of 22 mmHg (range 19–26 mmHg) after surgical thromboendarteriectomy, indicating a predominantly proximal increase in PVR. All of the patients were severely dyspnoeic and in New York Heart Association functional class III. None of the patients were being treated with prostacyclin analogues at the time of right heart catheterisation.

Procedures and measurements

Right heart catheterisation was performed without premedication, with the patient lying supine and breathing room air. A balloon-tipped, flow-directed, pulmonary catheter (131HF7; Baxter Healthcare Corp., Irvine, CA, USA) was inserted into an internal jugular vein under local anaesthetic and floated, under continuous pressure wave monitoring, into a pulmonary artery to measure Ppa, pulmonary artery occluded pressure (Ppao), Pc (computed from the Ppa decay curve), right atrial pressure (Pra) and pulmonary blood flow (Q). Systemic arterial pressure was determined intermittently by an automated blood pressure cuff. Heart rate was determined from a continuously monitored electrocardiographical lead. Transcutaneous arterial oxyhaemoglobin saturation was continuously monitored by pulse oxymetry.

Pulmonary vascular pressures were measured using disposable transducers (TruWave; Baxter Healthcare Corp.) connected to a bedside haemodynamic and electrocardiographical monitoring system (Sirecust 404; Siemens, Erlangen, Germany). The pressure transducers were zero referenced at mid-chest, and vascular pressures were obtained at end-expiration. Q was measured using the thermodilution technique as a mean of at least three successive measurements (COM‐2; Baxter Healthcare Corp.). Inhaled nitric oxide (NO) was supplied from a pure NO source tank (Oxhydrique, Machelen, Belgium) and delivered through a tight facemask. The inspired fraction of NO was monitored by chemiluminescence after calibration against standard NO concentration (42 chemiluminescence NO-NO2-Nox analyser; Thermo Environmental Instruments Inc., Franklin, MA, USA). The pulmonary vascular pressure signals were sampled at 200 Hz using an analogue-to-digital converter (DAS 8‐PGA; Keithley-Metrabyte, Taunton, MA, USA), and stored and analysed on a personal computer.

Pulmonary capillary pressure measurements

Pc was computed in triplicate from Ppa decay curves after inflation of the balloon of the pulmonary artery catheter. For this measurement, the patients were asked to stop breathing at the end of a normal tidal volume for 10 s. All Ppa signals were filtered using a two-pole digital low-pass filter with a cut-off at 18 Hz. The Ppa decay curves were analysed by two different methods. First, by fitting the data between 0.2–2 s post-occlusion with a mono-exponential equation and by deriving the pressure 152 ms after the moment of occlusion 6, 9. Second, by fitting the data between the moment of occlusion and the stabilisation of the pressure tracing at the level of the Ppao with a bi-exponential equation, and by the calculation of Pc with the exact solution for a three-compartment model of the pulmonary circulation formalised by Baconnier et al. 7, with a normalisation procedure to mean Ppa 10. PVRa was calculated as (Ppa–Pc)/Q and expressed as the percentage of PVR, calculated as (Ppa–Ppao)/Q.

Clinical evaluation

The clinical state of all of the PAH patients was assessed by a score made up of the following 16 symptoms and signs: fatigue, dyspnoea, orthopnoea, jugular vein distension, peripheral oedema, syncope, dizziness, palpitation, chest pain, loud second heart sound, third heart sound, fourth heart sound, right ventricular heave, systolic murmur, diastolic murmur and hepatomegaly 11.

Study protocol

As soon as steady-state conditions (stable heart rate and Ppa for 20 min) were ensured, a baseline set of haemodynamic measurements was obtained. The measurements were repeated after a 20-min equilibration period under inhalation of 20 parts per million of NO in 22 of the PAH patients. This dose of NO is two times the dose previously shown to offer a maximum pulmonary vasodilating effect in patients with PPH 12.

Statistical analysis

Results are presented as mean±se. Comparisons of haemodynamic variables at baseline and during inducible NO administrations in the same patients were made by paired t‐test. Linear correlations were calculated between haemodynamic variables and the signs and symptoms score.

Results

As shown in table 1⇓, the pulmonary haemodynamic profile of the PAH patients was similar to that previously reported in large series of patients with PPH, that is, very high Ppa, moderately increased Pra, normal Ppao and decreased Q 5, 11. Pc calculated from mono-exponential fitting was increased to 34±1 mmHg, with a PVRa of 48±2%. Pc calculated from bi-exponential fitting was lower (p<0.01), but still increased to an average of 26±1 mmHg, with a PVRa of 63±1%. All further reported Pc values were calculated from double exponential fitting procedure. Inhaled NO slightly decreased PVR, with small but significant decreases in Ppa and Pra. Inhaled NO did not change the partition of PVR.

View this table:
  • View inline
  • View popup
Table 1

Haemodynamics at baseline and during inhalation of 20 parts per million nitric oxide (NO) in patients with pulmonary arterial hypertension and at baseline in four patients with chronic thromboembolic pulmonary hypertension (CTEPH) and two patients with pulmonary veno-occlusive disease (PVOD)

The Ppa decay after occlusion was prolonged in the patients with PVOD and was shorter in the patients with CTEPH (fig. 1⇓). In comparison with the patients with PAH, those with PVOD had increased Pc and decreased PVRa. In patients with CTEPH, Pc was decreased and PVRa increased, but the measurements did not allow a clear discrimination between PAH, PVOD and CTEPH (fig. 2⇓).

Fig. 1.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 1.—

Typical pulmonary artery occlusion recordings used to estimate pulmonary capillary pressure (Pc) in a) a patient with a pulmonary arterial hypertension, b) a patient with pulmonary veno-occlusive disease and c) a patient with chronic thromboembolic pulmonary hypertension. The bi-exponential fittings are shown in dotted lines, and the evolution of Pc after occlusion (vertical solid lines) calculated with the three-compartment model of the pulmonary circulation in dashed lines.

Fig. 2.—
  • Download figure
  • Open in new tab
  • Download powerpoint
Fig. 2.—

a) Pulmonary capillary pressure (Pc) and b) arterial segment of pulmonary vascular resistance (PVRa) values in patients with pulmonary arterial hypertension (PAH), chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary veno-occlusive disease (PVOD). The solid line represents the mean value in PAH and CTEPH patients.

In the PAH patients, there was no correlation between Ppa, Pra or Pc and the clinical score, while PVR was directly correlated with the clinical score (r=0.384, p<0.05). Pc was correlated with Ppao (r=0.79, p<0.001) and Ppa (r=0.76, p<0.001).

Discussion

The present results show that compared to PAH, PVRa is increased in CTEPH and decreased in PVOD, but that isolated measurement of PVRa does not allow a differential diagnosis between these three types of severe PH.

Measurement of pulmonary capillary pressure versus pulmonary artery occlusion pressure

Inflation of the balloon at the tip of a pulmonary artery catheter to measure Ppao creates a downstream stop-flow phenomenon extending to same diameter veins. Therefore, Ppao generally gives a satisfactory estimate of left atrial or end-diastolic left ventricular pressure. Wedging a pulmonary artery catheter without balloon inflation yields a pulmonary artery wedge pressure, sometimes called a pulmonary capillary wedge pressure or (wrongly) a pulmonary capillary pressure, which measures the pressure of same diameter veins. Increased venous resistance may increase pulmonary artery wedge pressure relative to Ppao. The measurement of an effective pulmonary capillary pressure, Pc, requires the analysis of a Ppa decay curve after balloon occlusion 1, 2.

Computing of pulmonary capillary pressure

Based on pulmonary circulation, modelled as an electrical circuit made of a capillary capacitance between the arterial and venous resistances (R‐C‐R), the Ppa decay curve after balloon occlusion can be fitted with a mono-exponential function, and Pc can be calculated by extrapolation to the moment of occlusion or shortly thereafter 6. There is, however, a concern that Pc estimated from a mono-exponential fitting might overestimate capillary pressure, as measured by double occlusion or by the reference isogravimetric method 13, 14. Direct micropuncture measurements compared with single and double occlusion determinations suggest that Pc estimated from a mono-exponential fitting may be affected by small arterioles resistance in addition to capillary-venous resistance 15.

A better fit of Ppa decay curves after balloon occlusion is obtained with a bi-exponential function 16. Since both the arterial and venous segments of the pulmonary circulation can be characterised by resistive and compliant properties, Baconnier et al. 7 formalised a three-compartment C‐R‐C‐R‐C model, and proposed an exact solution to compute Pc from the bi-exponential fitting of the Ppa decay curve. As there is a phasic variation of Pcc within the cardiac cycle 17, Pc may be better normalised to mean Ppa 10. In the present study, this method of calculation led to lower Pc values than previously found using a mono-exponential fitting in PPH patients 3, 18. However, it is uncertain whether any contribution of the smallest size pulmonary arterioles to calculated Pc is excluded.

The present results confirm that Pc computed from mono-exponential fitting is very high in PAH 4. However, Pc derived from bi-exponential fitting was still higher than normal. Based on reported measurements of Ppa and Ppao in normal subjects, and a normal PVRa of ∼60% 3, Pc should not normally exceed 16 mmHg. Pc values that increased above 20 mmHg could be expected to be associated with an increased extravascular lung water 3. However, as lung oedema is not known as a usual feature of PAH 5, it is most likely that high Pc measured in PAH would be caused by the effect of increased smallest arteriolar resistance. An alternative, though less likely explanation, would be that the lungs of PAH patients, like patients with left heart failure, would be adapted to chronically increased capillary filtration pressure by capillary remodelling and increased lymphatic flow.

Mechanisms of increased pulmonary capillary pressure in pulmonary arterial hypertension

Histological studies in PPH show various combinations of medial hypertrophy, concentric or excentric intimal fibrosis, and complex arteritis, plexiform or dilatation lesions in ∼30% of cases, in situ thrombosis 19. These histological features seem nonspecific for PPH and are described in a variety of secondary forms of PAH, such as PH associated with anorexigen intake 19, CREST syndrome 20, HIV infection 21 and chronic liver disease 22. The lesions appear to predominate in small, <500–1,000 µm diameter, arterioles, but it is not entirely clear whether they might extend to more proximal portions of the pulmonary arterial tree, nor whether there might be coexistent lesions of small pulmonary veins.

Spontaneously hypertensive Wistar Kyoto rats that are used as a model of PH show increased muscularity in small pulmonary veins as well as in arteries 23. In a series of 19 patients with PPH, intimal and/or advential increased thickness of the pulmonary venous walls was found in half of them 24. Venous involvement is also present in PH associated with CREST syndrome 20. It has been estimated that 5–25% of patients with clinically diagnosed PPH present with predominant venoocclusive lesions at careful pathological examination of biopsic or autopsic specimens 25. PVOD has also been described in patients infected with HIV 21. Therefore, the present finding of increased absolute values of Pc with a “normal” longitudinal distribution of the PVR, may reflect that venous involvement is more important than previously assumed in patients with PAH. Detailed morphological studies will be needed to assess whether the variability of recorded Pc in the present study might reflect variability in this venous involvement in PAH.

Effects of inhaled nitric oxide in pulmonary arterial hypertension

These data show that inhaled NO decreases PVR without changing its partition. Inhaled NO has been reported in isolated perfused lungs of various species after different vasoconstrictor stimuli either to unalter the longitudinal distribution of resistances 26 or to act predominantly at precapillary level 27. Inhaled NO did not affect the longitudinal distribution of resistances in experimental micro-embolic PH 28 but decreased the capillary-venous component of PVR in acute respiratory distress syndrome 29. Inhaled NO diffuses easily through the alveolo-capillary membrane before its inactivation by haemoglobin, and probably dilates the smallest arterioles and venules adjacent to the alveolar space, provided there is a component of active constriction. These results confirm that in most patients with PAH, this component of vasoconstriction is minimal, and that inhaled NO dilates both arterioles and venules.

Clinical and haemodynamic correlations

In the present study, the signs and symptoms score was correlated with PVR and not Ppa or Pc. This is in keeping with previous studies showing that PVR or Q are better correlated with exercise or functional capacity in PAH patients than Ppa 30. There were significant correlations between Pc and Ppa or Ppao. This is explained by upstream transmission of left heart filling pressures, and by the fact that increased capillary-venous resistance necessarily increases both Ppa and Pc.

Clinical implications

There is only one previously reported patient with PVOD and Pc measured using the occlusion method 31. The present results do not agree with that study's suggestion that an increased Pc is diagnostic of PVOD.

Only two patients with PVOD could be included in the present study, precluding meaningful statistical comparisons with patients with PAH. This is explained by the fact that the disease is very rare, with an estimated incidence of 0.1–0.2 cases per million persons per year 25. In addition, these patients are often critically ill and unstable at the time of diagnosis, making the collection of sufficient quality arterial occlusion data problematic.

Most patients with CTEPH present with some degree of persistent PH after successful thromboendarteriectomy 32. In this study, a small series of four such patients, selected for minimal residual PH, had a Pc less elevated on average than in patients with PAH, but still higher than normal, suggestive of peripheral small vessel involvement. Whether the occlusion technique has the potential of helping the identification of patients with CTEPH at risk of postoperative PH is currently under investigation, with promising preliminary results 33.

Conclusions

In patients with pulmonary arterial hypertension, pulmonary capillary pressure measured with the occlusion technique is higher than normal and may be due to a previously assumed unimportant venous involvement. The single arterial occlusion technique helps to locate the site of predominantly increased pulmonary vascular resistance in severe pulmonary hypertension, but does not discriminate between pulmonary arterial hypertension, pulmonary veno-occlusive disease and chronic thromboembolic pulmonary hypertension.

Acknowledgments

The authors thank the staff of the Intensive Care Unit and the staff of the Coronary Care Unit of the Erasmus University Hospital (Brussels, Belgium) for their help with patient care. M‐T. Gautier and P. Jespers helped in the preparation of this report.

  • Received June 24, 2002.
  • Accepted August 19, 2002.
  • © ERS Journals Ltd

References

  1. ↵
    Cope DK, Allison RC, Parmentier JL, Miller JN, Taylor AE. Measurement of effective pulmonary capillary pressure using the pressure profile after pulmonary artery occlusion. Crit Care Med 1986;14:16–22.
    OpenUrlPubMedWeb of Science
  2. ↵
    Grimbert FA. Effective pulmonary capillary pressure. Eur Respir J 1988;1:297–301.
    OpenUrlFREE Full Text
  3. ↵
    Maggiorini M, Mélot C, Pierre S, et al. High altitude pulmonary edema is initially caused by an increased capillary pressure. Circulation 2001;103:2078–2083.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Kafi SA, Mélot C, Vachiery JL, Brimioulle S, Naeije R. Partitioning of pulmonary vascular resistance in primary pulmonary hypertension. J Am Coll Cardiol 1998;31:1372–1376.
    OpenUrlCrossRefPubMedWeb of Science
  5. ↵
    Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216–223.
  6. ↵
    Gilbert E, Hakim TS. Derivation of pulmonary capillary pressure from arterial occlusion in intact conditions. Crit Care Med 1994;22:986–993.
    OpenUrlPubMedWeb of Science
  7. ↵
    Baconnier PF, Eberhard A, Grimbert FA. Theoretical analysis of occlusion techniques for measuring pulmonary capillary pressure. J Appl Physiol 1992;73:1351–1359.
    OpenUrlAbstract/FREE Full Text
  8. ↵
    Fishman AP. . Clinical classification of pulmonary hypertension. Clin Chest Med 2001;22:385–391.
    OpenUrlCrossRefPubMedWeb of Science
  9. ↵
    Hakim TS, Maarek JM, Chang HK. Estimation of pulmonary capillary pressure in intact dog lungs using the arterial occlusion technique. Am Rev Respir Dis 1989;140:217–224.
    OpenUrlPubMedWeb of Science
  10. ↵
    Pagnamenta A, Bouckaert Y, Wauthy P, Brimioulle S, Naeije R. Continuous versus pulsatile pulmonary hemodynamics in canine oleic acid lung injury. Am J Respir Crit Care Med 2000;162:936–940.
    OpenUrlPubMedWeb of Science
  11. ↵
    Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 2002;162:800–804.
    OpenUrl
  12. ↵
    Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med 1995;151:384–389.
    OpenUrlPubMedWeb of Science
  13. ↵
    Townsley MI, Korthuis RJ, Rippe B, Parker JC, Taylor AE. Validation of double vascular occlusion method for Pc,i in lung and skeletal muscle. J Appl Physiol 1986;61:127–132.
    OpenUrlAbstract/FREE Full Text
  14. ↵
    Maarek JM, Hakim TS, Chang HK. Analysis of pulmonary arterial pressure profile after occlusion of pulsatile blood flow. J Appl Physiol 1990;68:761–769.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    Hakim TS, Kelly S. Occlusion pressures vs. micropipette pressures in the pulmonary circulation. J Appl Physiol 1989;67:1277–1285.
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Dawson CA, Bronikowski TA, Linehan JH, Haworth ST, Rickaby DA. On the estimation of pulmonary capillary pressure from arterial occlusion. Am Rev Respir Dis 1989;140:1228–1236.
    OpenUrlPubMedWeb of Science
  17. ↵
    Yamada Y, Suzukawa M, Chinzei M, et al. Phasic capillary pressure determined by arterial occlusion in intact dog lung lobes. J Appl Physiol 1989;67:2205–2211.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    Gaar KA Jr, Taylor AE, Owens LJ, Guyton AC. Pulmonary capillary pressure and filtration coefficient in the isolated perfused lung. Am J Physiol 1967;213:910–914.
    OpenUrlFREE Full Text
  19. ↵
    Pietra GG.. The pathology of pulmonary hypertensionIn: Rubin LJ, Rich S, editors. Primary Pulmonary HypertensionNew York, Marcel Dekker, 1997; pp. 19–61.
  20. ↵
    Yousem SA. The pulmonary pathologic manifestations of the CREST syndrome. Hum Pathol 1990;21:467–474.
    OpenUrlCrossRefPubMedWeb of Science
  21. ↵
    Mesa RA, Edell ES, Dunn WF, Edwards WD. Human immunodeficiency virus infection and pulmonary hypertension: two new cases and a review of 86 reported cases. Mayo Clin Proc 1998;73:37–45.
    OpenUrlCrossRefPubMedWeb of Science
  22. ↵
    Schraufnagel DE, Kay JM. Structural and pathologic changes in the lung vasculature in chronic liver disease. Clin Chest Med 1996;17:1–15.
    OpenUrlCrossRefPubMedWeb of Science
  23. ↵
    Aharinejad S, Schraufnagel DE, Bock P, et al. Spontaneously hypertensive rats develop pulmonary hypertension and hypertrophy of pulmonary venous sphincters. Am J Pathol 1996;148:281–290.
    OpenUrlPubMedWeb of Science
  24. ↵
    Chazova I, Loyd JE, Zhdanov VS, Newman JH, Belenkov Y, Meyrick B. Pulmonary artery adventitial changes and venous involvement in primary pulmonary hypertension. Am J Pathol 1995;146:389–397.
    OpenUrlPubMedWeb of Science
  25. ↵
    Mandel J, Mark EJ, Hales CA. Pulmonary veno-occlusive disease. Am J Respir Crit Care Med 2000;162:1964–1973.
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    Lindeborg DM, Kavanagh BP, van Meurs K, Pearl RG. Inhaled nitric oxide does not alter the longitudinal distribution of pulmonary vascular resistance. J Appl Physiol 1995;78:341–348.
    OpenUrlAbstract/FREE Full Text
  27. ↵
    Rimar S, Gillis CN. Site of pulmonary vasodilation by inhaled nitric oxide in the perfused lung. J Appl Physiol 1995;78:1745–1749.
    OpenUrlAbstract/FREE Full Text
  28. ↵
    Mélot C, Vermeulen F, Maggiorini M, Gilbert E, Naeije R. Site of pulmonary vasodilation by inhaled nitric oxide in microembolic lung injury. Am J Respir Crit Care Med 1997;156:75–85.
    OpenUrlPubMedWeb of Science
  29. ↵
    Rossetti M, Guenard H, Gabinski C. Effects of nitric oxide inhalation on pulmonary serial vascular resistances in ARDS. Am J Respir Crit Care Med 1996;154:1375–1381.
    OpenUrlPubMedWeb of Science
  30. ↵
    Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487–492.
    OpenUrlCrossRefPubMedWeb of Science
  31. ↵
    Davis LL, deBoisblanc BP, Glynn CE, Ramirez C, Summer WR. Effect of prostacyclin on microvascular pressures in a patient with pulmonary veno-occlusive disease. Chest 1995;108:1754–1756.
    OpenUrlCrossRefPubMedWeb of Science
  32. ↵
    Moser KM, Auger WR, Fedullo PF, Jamieson SW. Chronic thromboembolic pulmonary hypertension: clinical picture and surgical treatment. Eur Respir J 1992;5:334–342.
    OpenUrlAbstract/FREE Full Text
  33. ↵
    Kim HS, Fesler P, Channick RN, Naeije R, Rubin LJ. Pre-operative pulmonary artery occlusion measurements correlate with hemodynamic outcome following pulmonary thromboendarteriectomy. Am J Respir Crit Care Med Suppl 2002;165:A24.
    OpenUrl
PreviousNext
Back to top
View this article with LENS
Vol 21 Issue 1 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Single arterial occlusion to locate resistance in patients with pulmonary hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Citation Tools
Single arterial occlusion to locate resistance in patients with pulmonary hypertension
P. Fesler, A. Pagnamenta, J‐L. Vachiéry, S. Brimioulle, S. Abdel Kafi, A. Boonstra, M. Delcroix, R.N. Channick, L.J. Rubin, R. Naeije
European Respiratory Journal Jan 2003, 21 (1) 31-36; DOI: 10.1183/09031936.03.00054202

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Single arterial occlusion to locate resistance in patients with pulmonary hypertension
P. Fesler, A. Pagnamenta, J‐L. Vachiéry, S. Brimioulle, S. Abdel Kafi, A. Boonstra, M. Delcroix, R.N. Channick, L.J. Rubin, R. Naeije
European Respiratory Journal Jan 2003, 21 (1) 31-36; DOI: 10.1183/09031936.03.00054202
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo
Full Text (PDF)

Jump To

  • Article
    • Abstract
    • Methods
    • Results
    • Discussion
    • Acknowledgments
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Endogenous endothelins and nitric oxide in hypoxic pulmonary vasoconstriction
  • Genetic polymorphisms associated with acute pulmonary embolism and deep venous thrombosis
Show more Original Articles: Bench to Bedside: Pulmonary Circulation

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society